Share on StockTwits

Achillion Pharmaceuticals (NASDAQ:ACHN)‘s stock had its “buy” rating reaffirmed by stock analysts at Maxim Group in a report issued on Friday.

Shares of Achillion Pharmaceuticals (NASDAQ:ACHN) traded up 12.32% during mid-day trading on Friday, hitting $9.48. 17,268,546 shares of the company’s stock traded hands. Achillion Pharmaceuticals has a 1-year low of $2.26 and a 1-year high of $8.68. The stock’s 50-day moving average is $7.2 and its 200-day moving average is $4.54. The company’s market cap is $927.0 million.

Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its earnings results on Thursday, August 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.02. Analysts expect that Achillion Pharmaceuticals will post $-0.74 EPS for the current fiscal year.

ACHN has been the subject of a number of other recent research reports. Analysts at FBR Capital Markets initiated coverage on shares of Achillion Pharmaceuticals in a research note on Friday. They set an “outperform” rating and a $12.00 price target on the stock. Separately, analysts at Piper Jaffray upgraded shares of Achillion Pharmaceuticals from a “neutral” rating to an “overweight” rating in a research note on Monday. They now have a $10.00 price target on the stock, up previously from $5.00. Finally, analysts at Wells Fargo & Co. upgraded shares of Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Monday. They now have a $10.00 price target on the stock, up previously from $7.36. One analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $7.80.

Achillion Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.